
Christen Bertel Lykkegaard Andersen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1318646/publications.pdf Version: 2024-02-01



Christen Bertel Lykkegaard

#	Article	IF	CITATIONS
1	A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia. Leukemia Research, 2022, 112, 106756.	0.8	3
2	Biochemical abnormalities among patients referred for celiac disease antibody blood testing in a primary health care setting. Scientific Reports, 2022, 12, 6407.	3.3	4
3	A retrospective cohort study of patients with eosinophilia referred to a tertiary centre Danish Medical Journal, 2022, 69, .	0.5	Ο
4	Pre-diagnostic trajectories of lymphocytosis predict time to treatment and death in patients with chronic lymphocytic leukemia. Communications Medicine, 2022, 2, .	4.2	2
5	MO518: Chronic Kidney Disease in Primary Care and the Risk of Cardiovascular Comorbidity and Mortality. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	Ο
6	Incidence of New-Onset Type 2 Diabetes After Cancer: A Danish Cohort Study. Diabetes Care, 2022, 45, e105-e106.	8.6	7
7	Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival. British Journal of Haematology, 2021, 192, e81-e84.	2.5	2
8	Influence of educational level on test and treatment for incident hypothyroidism. Clinical Endocrinology, 2021, 94, 1025-1034.	2.4	4
9	Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic. Covid, 2021, 1, 303-314.	1.5	Ο
10	Risk of over- and under- treatment with levothyroxine in primary care in Copenhagen, Denmark. European Journal of Endocrinology, 2021, 185, 673-679.	3.7	9
11	Labor Market Attachment in Patients with Myeloproliferative Neoplasms: A Nationwide Matched Cohort Study. Blood, 2021, 138, 3627-3627.	1.4	Ο
12	Strategies to improve patient-reported outcome completion rates in longitudinal studies. Quality of Life Research, 2020, 29, 335-346.	3.1	27
13	Ageâ€related prevalence and clinical significance of neutropenia ―isolated or combined with other cytopenias: Real world data from 373 820 primary care individuals. American Journal of Hematology, 2020, 95, 521-528.	4.1	10
14	Health-Related Quality of Life in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Nationwide Population-Based Survey in Denmark. Cancers, 2020, 12, 3565.	3.7	10
15	Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association. Cancers, 2020, 12, 2202.	3.7	13
16	The Copenhagen Primary Care Laboratory Pregnancy (CopPreg) database. BMJ Open, 2020, 10, e034318.	1.9	6
17	Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica, 2020, 105, 2262-2272.	3.5	67
18	Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Clinical Epidemiology, 2019, Volume 11, 23-33.	3.0	18

CHRISTEN BERTEL LYKKEGAARD

#	Article	IF	CITATIONS
19	Association of the blood eosinophil count with end-organ symptoms. Annals of Medicine and Surgery, 2019, 45, 11-18.	1.1	11
20	Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. Experimental Hematology, 2019, 79, 26-34.	0.4	8
21	Epstein-Barr virus and its association with disease - a review of relevance to general practice. BMC Family Practice, 2019, 20, 62.	2.9	108
22	Changes in Prescription Routines for Treating Hypothyroidism Between 2001 and 2015: An Observational Study of 929,684 Primary Care Patients in Copenhagen. Thyroid, 2019, 29, 910-919.	4.5	43
23	Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis. Leukemia and Lymphoma, 2019, 60, 2549-2557.	1.3	5
24	Clarithromycin added to bortezomibâ€cyclophosphamideâ€dexamethasone impairs healthâ€related quality of life in multiple myeloma patients. European Journal of Haematology, 2019, 102, 70-78.	2.2	8
25	Thromboembolism prophylaxis in patients with Philadelphia-negative myeloproliferative neoplasms-Clinical practice among Nordic specialists. European Journal of Haematology, 2018, 100, 475-478.	2.2	1
26	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. New England Journal of Medicine, 2018, 379, 1416-1430.	27.0	442
27	The development of multimorbidity during 16 years after diagnosis of type 2 diabetes. Journal of Comorbidity, 2018, 8, 2235042X1880165.	3.9	12
28	Brain Natriuretic Peptide in Plasma as Predictor of All-Cause Mortality in a Large Danish Primary Health Care Population Suspected of Heart Failure. Clinical Chemistry, 2018, 64, 1723-1731.	3.2	9
29	Safety and efficacy of combination therapy of interferonâ€Î±2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Medicine, 2018, 7, 3571-3581.	2.8	38
30	Interpretation of HbA _{1c} in primary care and potential influence of anaemia and chronic kidney disease: an analysis from the Copenhagen Primary Care Laboratory (CopLab) Database. Diabetic Medicine, 2018, 35, 1700-1706.	2.3	19
31	A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma. Experimental Hematology and Oncology, 2018, 7, 18.	5.0	9
32	A systematic review of healthâ€related quality of life in longitudinal studies of myeloma patients. European Journal of Haematology, 2017, 99, 3-17.	2.2	54
33	Anemia is present years before myelodysplastic syndrome diagnosis: Results from the preâ€diagnostic period. American Journal of Hematology, 2017, 92, E130-E132.	4.1	5
34	Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations. Scientific Reports, 2017, 7, 6774.	3.3	16
35	A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents. Clinical Epidemiology, 2017, Volume 9, 141-150.	3.0	8
36	The Danish National Chronic Myeloid Neoplasia Registry. Clinical Epidemiology, 2016, Volume 8, 567-572.	3.0	11

#	Article	IF	CITATIONS
37	Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study. Journal of Internal Medicine, 2016, 279, 566-575.	6.0	31
38	A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms. Quality of Life Research, 2016, 25, 835-846.	3.1	15
39	Health-Related Quality of Life (HRQoL) Measurements in Multiple Myeloma Patients Obtained By EORTC QLQ-C30; A Critical Review of Interpreting HRQoL Data in Longitudinal Studies. Blood, 2016, 128, 540-540.	1.4	1
40	Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial. Blood, 2016, 128, 5479-5479.	1.4	0
41	Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. Oncotarget, 2015, 6, 40588-40597.	1.8	14
42	<scp>A</scp> ssociation of the blood eosinophil count with hematological malignancies and mortality. American Journal of Hematology, 2015, 90, 225-229.	4.1	20
43	Is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer?. Gynecologic Oncology, 2015, 139, 312-318.	1.4	10
44	Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study. Blood, 2015, 126, 824-824.	1.4	14
45	The Copenhagen Primary Care Differential Count (CopDiff) database. Clinical Epidemiology, 2014, 6, 199.	3.0	16
46	Eosinophilia in routine blood samples as a biomarker for solid tumor development – A study based on The Copenhagen Primary Care Differential Count (CopDiff) Database. Acta Oncológica, 2014, 53, 1245-1250.	1.8	9
47	A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis. Haematologica, 2014, 99, e5-e7.	3.5	22
48	Circulating <scp>YKL</scp> â€40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. European Journal of Haematology, 2014, 93, 224-228.	2.2	21
49	The prevalence and prognostic value of concomitant eosinophilia in chronic graft-versus-host disease after allogeneic stem cell transplantation. Leukemia Research, 2014, 38, 334-339.	0.8	5
50	Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research, 2014, 38, 816-821.	0.8	12
51	Risk of Lymphoma and Solid Cancer among Patients with Rheumatoid Arthritis in a Primary Care Setting. PLoS ONE, 2014, 9, e99388.	2.5	15
52	Prediagnostic Thrombocytosis Increases the Risk of Advanced Gynecological Cancer and Increases Mortality Independently of Cancer Stage – a Population-Based Study. Blood, 2014, 124, 2791-2791.	1.4	0
53	DNA Methylation Profiling of Sorted Cells from Myelofibrosis Patients reveals Aberrant Epigenetic Regulation of Immune Pathways and identifies Early MPN Driver Genes. Blood, 2014, 124, 4576-4576.	1.4	0
54	A phase II study of vorinostat (<scp>MK</scp> â€0683) in patients with polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 2013, 162, 498-508.	2.5	65

#	Article	IF	CITATIONS
55	Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. Leukemia Research Reports, 2013, 2, 1-3.	0.4	30
56	Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death. American Journal of Hematology, 2013, 88, 843-847.	4.1	33
57	Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial. Blood. 2013, 122, 4090-4090.	1.4	7
58	Risks of Eosinophil-Related End-Organ Damage, Hematological Malignancies and Death Are Significantly Increased Even below Consensus Threshold Criteria for Blood Eosinophilia. Blood, 2013, 122, 2831-2831.	1.4	1
59	Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms. Leukemia Research, 2012, 36, 485-487.	0.8	6
60	Symptom Burden Among PV and ET Patients Receiving A Novel Histone Deacetylase Inhibitor: Findings From a Open-Label Phase II Study. Blood, 2012, 120, 1736-1736.	1.4	1
61	A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia. Blood, 2012, 120, 803-803.	1.4	4
62	Systemic mastocytosisa systematic review. Danish Medical Journal, 2012, 59, A4397.	0.5	12